- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00907777
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine
The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously vaccinated with 3 primary doses of GSK 1024850A or Prevenar™ vaccine within the first 6 months of life and a booster dose of plain polysaccharide pneumococcal (Pneumovax 23™) vaccine at 11-14 months of age.
Antibody persistence will also be assessed at approximately 4 years of age in children previously vaccinated with 3 doses of either GSK 1024850A or Prevenar™ vaccine followed by a booster dose of Pneumovax 23™.
This protocol posting deals with objectives & outcome measures of the extension phase at year 4. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT 00307541). The objectives & outcome measures of the booster phase are presented in a separate protocol posting (NCT 00333450).
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10315
- GSK Investigational Site
-
Berlin, Germany, 13055
- GSK Investigational Site
-
Berlin, Germany, 14197
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Mannheim, Baden-Wuerttemberg, Germany, 68163
- GSK Investigational Site
-
-
Bayern
-
Noerdlingen, Bayern, Germany, 86720
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Bad Oeynhausen, Nordrhein-Westfalen, Germany, 32549
- GSK Investigational Site
-
Goch, Nordrhein-Westfalen, Germany, 47574
- GSK Investigational Site
-
Heiligenhaus, Nordrhein-Westfalen, Germany, 42579
- GSK Investigational Site
-
Moenchengladbach, Nordrhein-Westfalen, Germany, 41061
- GSK Investigational Site
-
Moenchengladbach, Nordrhein-Westfalen, Germany, 41236
- GSK Investigational Site
-
Willich, Nordrhein-Westfalen, Germany, 47877
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Frankenthal, Rheinland-Pfalz, Germany, 67227
- GSK Investigational Site
-
Mainz, Rheinland-Pfalz, Germany, 55131
- GSK Investigational Site
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04178
- GSK Investigational Site
-
-
Thueringen
-
Lobenstein, Thueringen, Germany, 07356
- GSK Investigational Site
-
Neuhaus am Rennweg, Thueringen, Germany, 98724
- GSK Investigational Site
-
Weimar, Thueringen, Germany, 99425
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female between, and including, 46-50 months of age at the time of vaccination.
- Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
- Subjects who previously participated in study NCT00333450 in centres with more than 2 subjects and received a booster dose of Pneumovax 23™.
- Written informed consent obtained from both parents/guardians of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
Exclusion Criteria:
- Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the vaccination, or planned use during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination.
- Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before study vaccination and during the entire study period.
- Administration of any pneumococcal vaccine since the end of study NCT00333450.
- Administration of immunoglobulins and/or any blood products less than 3 months prior to the vaccination or planned use during the study period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical
- History of any neurologic disorders or seizures
- Anaphylactic reaction following previous administration of the vaccine or history of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
- History of hypotonic-hyporesponsive episode after any previous vaccination.
- Major congenital defects or serious chronic illness.
- History of invasive pneumococcal diseases.
- Acute disease at the time of vaccination
- Rectal temperature >= 38.0°C or oral/axillary/tympanic temperature >= 37.5°C. A temperature greater than or equal to these cut-offs warrants deferral of the vaccination pending recovery of the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pn Group
Subjects receiving GSK 1024850A vaccine.
|
One dose of vaccine will be injected intramuscularly into the deltoid.
|
ACTIVE_COMPARATOR: Prev Group
Subjects receiving Prevenar™ vaccine.
|
One dose of vaccine will be injected intramuscularly into the deltoid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine Pneumococcal Serotype Antibody Concentrations
Time Frame: Before (PRE) and one month after (POST) the additional dose
|
The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
Before (PRE) and one month after (POST) the additional dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes
Time Frame: Before (PRE) and one month after (POST) the additional dose
|
The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
Before (PRE) and one month after (POST) the additional dose
|
Cross-reactive Pneumococcal Serotype Antibody Concentrations
Time Frame: Before (PRE) and one month after (POST) the additional dose
|
The anti-pneumococcal antibody concentration cut-off value assessed was greater than or equal to ≥ 0.05 microgram per milliliter (μg/mL).
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
|
Before (PRE) and one month after (POST) the additional dose
|
Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes
Time Frame: Before (PRE) and one month after (POST) the additional dose
|
The opsonophagocytic activity cut-off value assessed was greater than or equal to ≥ 8.
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
|
Before (PRE) and one month after (POST) the additional dose
|
Anti-protein D Antibody Concentrations
Time Frame: Before (PRE) and one month after (POST) the additional dose
|
The anti-protein D antibody cut-off value (greater than or equal to ≥100 EL.U/mL) was assessed by Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).
|
Before (PRE) and one month after (POST) the additional dose
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
Time Frame: During the 8-day (Days 0-7) post-additional dose
|
Solicited local symptoms assessed include pain, redness, and swelling.
Grade 3 pain was defined as crying when limb was moved/spontaneously painful.
Grade 3 swelling/redness was defined as swelling/redness larger (>) 30 millimeters (mm).
"Any" is defined as incidence of the specified symptom regardless of intensity.
|
During the 8-day (Days 0-7) post-additional dose
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Time Frame: During the 8-day (Days 0-7) post-additional dose
|
Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite.
Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities.
Grade 3 fever was defined as fever (rectal temperature) above (>) 40.0 degree Celsius (°C).
Grade 3 irritability was defined as crying that could not be comforted/preventing normal everyday activities.
Grade 3 loss of appetite was defined as the subject not eating at all.
"Any" is defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.
|
During the 8-day (Days 0-7) post-additional dose
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Time Frame: Within 31 days (Day 0-30) post-additional vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
"Any" is defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
|
Within 31 days (Day 0-30) post-additional vaccination
|
Number of Subjects With Serious Adverse Events (SAEs)
Time Frame: Throughout the entire study period (approximately 1 month per subject)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above.
|
Throughout the entire study period (approximately 1 month per subject)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Pneumococcal
- Streptococcal Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- 112807
- 2008-007605-37 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Study Data/Documents
-
Individual Participant Data Set
Information identifier: 112807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 112807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 112807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 112807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 112807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 112807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Streptococcus Pneumoniae
-
Universidad de la SabanaRecruitingCommunity-acquired Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae Pneumonia | Streptococcus Pneumoniae Infection InvasiveColombia
-
PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStreptococcus Pneumoniae InfectionsChina
-
University of OxfordPfizerUnknownStreptococcal Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae, Invasive DiseaseUnited Kingdom
-
UMC UtrechtNetherlands: Ministry of Health, Welfare and Sports; Netherlands Vaccine InstituteCompletedStreptococcus Pneumoniae Infection
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae VaccinesSweden
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalMexico
-
Arto PalmuGlaxoSmithKlineCompletedNasopharyngeal Carriage of Streptococcus PneumoniaeFinland
-
GlaxoSmithKlineWithdrawnImmunisation Against Streptococcus Pneumoniae
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalMexico
Clinical Trials on Pneumococcal conjugate vaccine GSK 1024850A
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniPoland
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae VaccinesSpain, Germany, Poland
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae | Infections, StreptococcalFinland
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae | Infections, StreptococcalFinland
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalSpain, Greece
-
GlaxoSmithKlineCompletedInfections, StreptococcalKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, StreptococcalNetherlands
-
GlaxoSmithKlineCompletedInfections, StreptococcalGermany, Czechia, Sweden, Poland
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruitingConsistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate VaccineHealthy VolunteersChina
-
SanofiCompletedPneumoccocal ImmunisationUnited States